SEI Investments’s ADMA Biologics ADMA Stock Holding History

SEI Investments’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7M	Sell	202,525 -87,835	-30%	-$801K	﹤0.01%	2028
2026 Q1	$2.62M	Buy	290,360 +854	+0.3%	+$13.5K	﹤0.01%	1874
2025 Q4	$5.28M	Sell	289,506 -224,454	-44%	-$3.78M	0.01%	1345
2025 Q3	$7.53M	Sell	513,960 -82,427	-14%	-$1.41M	0.01%	1127
2025 Q2	$10.9M	Buy	596,387 +93,272	+19%	+$1.9M	0.01%	946
2025 Q1	$9.98M	Sell	503,115 -24,157	-5%	-$418K	0.01%	970
2024 Q4	$9.04M	Buy	527,272 +314,013	+147%	+$5.91M	0.01%	1028
2024 Q3	$4.26M	Sell	213,259 -118,291	-36%	-$1.84M	0.01%	1361
2024 Q2	$3.71M	Sell	331,550 -61,931	-16%	-$520K	0.01%	1356
2024 Q1	$2.6M	Buy	393,481 +250,925	+176%	+$1.37M	﹤0.01%	1508
2023 Q4	$644K	Buy	142,556 +47,159	+49%	+$174K	﹤0.01%	2015
2023 Q3	$342K	Sell	95,397 -993	-1%	-$3.82K	﹤0.01%	2260
2023 Q2	$356K	Hold	96,390	–	–	﹤0.01%	2262
2023 Q1	$319K	Sell	96,390 -12,257	-11%	-$42.4K	﹤0.01%	2317
2022 Q4	$422K	Buy	+108,647	New	+$335K	﹤0.01%	2082

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SEI Investments's ADMA Position: Q2 2026 in Review

SEI Investments reduced its ADMA Biologics (ADMA) stake by 30% in Q2 2026, selling an estimated $801K and leaving 202,525 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

SEI Investments first reported a position in ADMA in Q4 2022 and has held it in 15 quarters since. The position peaked at $10.9M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

SEI Investments held 202,525 shares of ADMA Biologics worth $1.7M as of Q2 2026.
SEI Investments sold 87,835 ADMA Biologics shares in Q2 2026, an estimated $801K.
ADMA Biologics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2028 holding.
SEI Investments first reported a position in ADMA Biologics in Q4 2022 and has held it in 15 quarters since.
SEI Investments's ADMA Biologics position peaked at $10.9M in Q2 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.